CANDEL THERAPEUTICS INC. - COMMON STOCK

Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

16 Dec 2024 15:01:00 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Pricing of Public Offering

12 Dec 2024 22:00:53 By Nasdaq GlobeNewswire

Candel Therapeutics Announces $80 Million Proposed Public Offering

12 Dec 2024 15:51:06 By Nasdaq GlobeNewswire

Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

11 Dec 2024 06:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

14 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024

07 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma

05 Nov 2024 08:00:32 By Nasdaq GlobeNewswire

Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)

28 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting

04 Oct 2024 08:00:45 By Nasdaq GlobeNewswire

Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

03 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

13 Aug 2024 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

18 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics to Join Russell 3000® Index

11 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma

30 May 2024 07:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting

23 May 2024 16:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics to Present at the Jefferies Global Healthcare Conference

22 May 2024 07:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting

20 May 2024 07:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

14 May 2024 07:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

25 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer

11 Apr 2024 08:00:00 By Nasdaq GlobeNewswire